Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a single center, prospective, randomized, double blinded placebo controlled study
conducted I patients with type 1 diabetes.The aim of this study is to examine the additive
effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of
possible improved glycemic control, reduced glycemic variability, reduced insulin dosages,
additional effects of weight loss and blood pressure reduction.